Leishmanicidal activity of racemic ± 8-[(4-Amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline

• Published in: Natural product communications Vol. 5; no. 3; pp. 387 - 390
• Main Authors: Isaac-Márquez, Angélica P., McChesney, James D., Nanayakara, N.P. Dammika, Satoskar, Abhay R., Lezama-Dávila, Claudio M.
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.03.2010
• Subjects: Animals; Antiprotozoal Agents - chemistry; Antiprotozoal Agents - toxicity; Cell Survival - drug effects; HeLa Cells; Humans; Leishmania mexicana - drug effects; Leishmania mexicana - growth & development; Leishmania mexicana - ultrastructure; Lethal Dose 50; Meglumine - pharmacology; Motor Activity - drug effects; Organometallic Compounds - pharmacology; Quinolines - chemistry; Quinolines - toxicity; 8-aminoquinolines; leishmanicidal activity; cutaneous leishmaniasis; chiclero's ulcer; Leishmania (L.) mexicana
• ISSN: 1934-578X; 1555-9475
• DOI: 10.1177/1934578X1000500309

In this work we studied the in vitro toxicity of ± 8-[(4-Amino-1-Methylbutyl)Amino]-6-Methoxy-4-Methyl-5-[3,4-dichlorophenoxy]quinoline (DN3-27-1) against stationary phase promastigotes Leishmania (L.) mexicana. Our results indicate that this drug induces an important reduction in parasite growth and killing compared to the reference drug N-methyl meglumine (Glucantime™). DN3-27-1 was not toxic to Hela cells cultured in vitro. This is the first report describing the promising potential of DN3-27-1 in treatment of L. (L.) mexicana infections.